Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Work In Process (2020 - 2025)

Historic Work In Process for Karyopharm Therapeutics (KPTI) over the last 6 years, with Q4 2025 value amounting to $3.0 million.

  • Karyopharm Therapeutics' Work In Process fell 1586.67% to $3.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.0 million, marking a year-over-year decrease of 1586.67%. This contributed to the annual value of $3.0 million for FY2025, which is 1586.67% down from last year.
  • According to the latest figures from Q4 2025, Karyopharm Therapeutics' Work In Process is $3.0 million, which was down 1586.67% from $2.9 million recorded in Q3 2025.
  • Karyopharm Therapeutics' Work In Process' 5-year high stood at $4.2 million during Q2 2025, with a 5-year trough of $781000.0 in Q1 2021.
  • For the 5-year period, Karyopharm Therapeutics' Work In Process averaged around $2.3 million, with its median value being $1.9 million (2021).
  • As far as peak fluctuations go, Karyopharm Therapeutics' Work In Process skyrocketed by 19334.37% in 2021, and later tumbled by 4068.39% in 2023.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Work In Process stood at $1.9 million in 2021, then decreased by 0.9% to $1.9 million in 2022, then fell by 7.77% to $1.7 million in 2023, then skyrocketed by 104.5% to $3.5 million in 2024, then dropped by 15.87% to $3.0 million in 2025.
  • Its Work In Process was $3.0 million in Q4 2025, compared to $2.9 million in Q3 2025 and $4.2 million in Q2 2025.